Brought to you by 
GPC Biotech and Pharmion co-develop satraplatin;ends
07 Aug 2008
Executive Summary
GPC Biotech (cancer therapeutics) has licensed to Pharmion (hematology and oncology) exclusive rights to commercialize the Phase III cancer candidate satraplatin for hormone refractory prostate cancer (HRPC) in Europe, Turkey, the Middle East, Australia, and New Zealand.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GPC Biotech and Pharmion co-develop satraplatin;ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice